Podcast and Survey: Clinical features of acromegaly. In this podcast, Dr. Blevins dives into those clinical features of Acromegaly with a fascinating discussion about symptoms and signs and gives us an unfettered glimpse into the
From the editors’ desk – A recent Endocrine Web article by Kimberly B. Bjugstad Ph.D. highlights a new oral octreotide drug for Acromegaly. The drug currently is on an FDA Phase III trial, referred to as OPTIMAL,
In a press release today, San Diego, California based Crinetics Pharmaceuticals reports positive results from their Phase Two trial of PALTUSOTINE (the former CRN00808). This is a new oral medication to treat acromegaly and neuroendocrine
Your insights matter. From J D Faccinetti – co-founder and chief editor – In the awareness business coming up with new, fresh, creative ideas is essential to get your message across, particularly these days when breaking
A few weeks ago, Dan Jeffreys, a UK based author, musician, and patient advocate sent me a message to tell me about his latest project. He told me he started AcroTales to encourage people to share their
We are thrilled to announce that Acromegaly will be the focus of a PFDD (Patient-Focused Drug Development) meeting sponsored by Acromegaly Community Inc., a patient support organization based in the US. The meeting will take
November 1 is World Acromegaly Day! This fun video from the Asociacion Española de Afectados por Acromegalia is a great way to explain the causes and get more details on this disease. Excellent work from
From the desk of J D Faccinetti – cofounder. We often scan the world for compelling stories that broaden the awareness of pituitary disease and do it well. This one comes from Raquel Ciriza, the president
As we reported earlier this year, the acromegaly new drug development world has seen very exciting activity. Several studies are in the pipeline for oral therapies. Today, San Diego California based Crinetics Pharmaceuticals announced a new
In this podcasts, we discuss an important recent meta-analysis study from the University of Rome on the relationship between pegvisomant, a drug used for the treatment of acromegaly, and glucose metabolism. Dr. Blevins also dives into
Antisense drugs are small DNA – or RNA – drugs that are designed to target disease-associated proteins with the objective of slowing or stopping the progression of a disease. Ionis pharmaceuticals, in this new trial, is developing